In order to properly evaluate PD-1/PD-L1–inhibitor efficacy in EGFR-mutated and ALK-translocated NSCLC patients, prospective trials specifically enrolling patients with these profiles are needed. This evidence concerns the gene CD274 and non-small cell lung carcinoma.